Provided by Tiger Trade Technology Pte. Ltd.

Amgen

391.27
-1.9000-0.48%
Pre-market: 392.751.48+0.38%04:32 EDT
Volume:2.92M
Turnover:1.15B
Market Cap:210.69B
PE:24.30
High:395.55
Open:393.07
Low:389.28
Close:393.17
52wk High:447.03
52wk Low:269.77
Shares:538.48M
Float Shares:536.99M
Volume Ratio:0.98
T/O Rate:0.54%
Dividend:9.80
Dividend Rate:2.50%
EPS(TTM):16.10
EPS(LYR):14.23
ROE:91.47%
ROA:8.67%
PB:18.03
PE(LYR):27.50

Loading ...

Ionis Pharma Tumbles After Heart Drug Fails Late-Stage Trial

Reuters
·
Sep 08

Rothschild & Co Redburn Adjusts Price Target on Amgen to $225 From $235, Keeps Sell Rating

MT Newswires Live
·
Sep 08

Why Amgen Stock is Dropping After Swiss Rival's Trial Setback

Dow Jones
·
Sep 08

Amgen Falls After Novartis Trial Setback, BMO Downgrade

Reuters
·
Sep 08

Stocks to Watch: Amgen, Nike, Bloom Energy

Dow Jones
·
Sep 08

Amgen downgraded to Market Perform from Outperform at BMO Capital

TIPRANKS
·
Sep 08

Amgen Shares Down 5.4% Premarket; Rival Novartis Cholesterol Drug Fails Late-Stage Study

THOMSON REUTERS
·
Sep 08

Why the Dow is Being Dragged Down by a Swiss Company's Bad News

Dow Jones
·
Sep 08

Movement Alert|Amgen Falls 5.08% in Pre-Market Trading, Novartis Lp(a) Heart Drug Phase III Failure Drags Down Peer Stocks

Market Focus
·
Sep 08

Movement Alert|Amgen Overnight Decline 5.27%, Dragged by Novartis Lp(a) Drug Trial Failure Casting Doubt on Cardiovascular Pipeline Thesis

Market Focus
·
Sep 08

Sino Biopharmaceutical Stock Slides 1.2% in Hong Kong, Underperforms Competitors

Dow Jones
·
Sep 07

Novartis Cholesterol Setback Tests Hopes for Emerging Heart Disease Drugs

Reuters
·
Sep 07

Second Clinical Trial Blow in a Week for Novartis as Heart Drug Disappoints, Dragging Down Amgen Shares

Stock News
·
Sep 07

A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?

Dow Jones
·
Sep 06

Amgen EVP, CFO Thomas J.W. Dittrich Files Initial Beneficial Ownership Statement

Reuters
·
Sep 05

Movement Alert|Amgen Falls 5.08% in After-Hours Trading, Trading at $409.94

Market Focus
·
Sep 05

Amgen is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Sep 05

Wells Fargo Adjusts Price Target on Amgen to $435 From $400, Keeps Equalweight Rating

MT Newswires Live
·
Sep 04

Political and General News Events from September 3

Reuters
·
Sep 03

Sino Biopharmaceutical Stock Rises 6.3% in Hong Kong, Outperforms Competitors

Dow Jones
·
Sep 03